Study shows that adalimumab led to sustained clinical and functional responses in nearly one-third of treatment-refractory patients who completed 10 years of treatment. Patients with shorter disease duration achieved better outcomes, highlighting the need for early treatment.
A recent review looked at the immunopathogenesis of psoriasis, identified key mediators of psoriatic plaques that are being targeted by new and emerging biologic therapies, and highlighted the latest efficacy and safety data from trials of these new agents.
Treatment with anti-TNF drugs and DMARDs is associated with clinically significant improvement measures of work disability such as presenteeism and productivity loss in patients with psoriatic arthritis.
Inflammatory chronic diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis bring many treatment challenges. Among them is the fact that biologic therapies for these diseases—particularly anti-TNF agents—while effective, can themselves bring reactivation of a latent tuberculosis infection.